Literature DB >> 23248431

Hemolytic uremic syndrome and E. coli infection in cancerous patients: A topic to be discussed in oncology.

Viroj Wiwanitkit1.   

Abstract

Entities:  

Year:  2012        PMID: 23248431      PMCID: PMC3523482          DOI: 10.4103/0971-5851.103154

Source DB:  PubMed          Journal:  Indian J Med Paediatr Oncol        ISSN: 0971-5851


× No keyword cloud information.
Sir, The E. coli outbreak in Europe is a big problem at present. The E. coli serotype O104:H4 is the cause of the present epidemic. One thousand infected cases are reported, with some deaths. The complication, namely hemolytic uremic syndrome (HUS), is the problem to be followed-up in the patients. Because the present epidemic is a community-acquired infection that is proved to increase the risk in cancer patients, it is interesting to discuss the nature of HUS in this group of patients. However, there is no present evidence that the HUS will be more serious in cancerous patients. Indeed, E. coli infection among the people with cancers is usually more severe than in the general population, but there is no specific study on HUS. Generally, HUS is well described in E. coli O157 infection, but it is also reported in the present O104 infection. Of interest, HUS is also described in relation with some treatments for cancerous patients. In interleukin treatment, induction of HUS is reported.[12] In addition, HUS can also be seen in cases with occult cancer.[3] However, this cannot lead to the conclusion that HUS will be more serious or more increased in prevalence in E. coli-infected cancerous patients.
  3 in total

1.  Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome associated with high-dose interleukin-2 for the treatment of metastatic melanoma.

Authors:  Doru T Alexandrescu; Prasad Maddukuri; Peter H Wiernik; Janice P Dutcher
Journal:  J Immunother       Date:  2005 Mar-Apr       Impact factor: 4.456

Review 2.  Thrombotic microangiopathy and occult neoplasia.

Authors:  Maria Teresa Pirrotta; Alessandro Bucalossi
Journal:  Cardiovasc Hematol Disord Drug Targets       Date:  2010-06

3.  Thrombotic microangiopathy associated with interferon therapy for patients with chronic myelogenous leukemia: coincidence or true side effect?

Authors:  F Ravandi-Kashani; J Cortes; M Talpaz; H M Kantarjian
Journal:  Cancer       Date:  1999-06-15       Impact factor: 6.860

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.